ASCO 2019: Bevacizumab Fails to Add Benefit to Chemotherapy for Metastatic Urothelial Carcinoma
The current standard of care remains cisplatin-based chemotherapy without a biologic agent
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.